Nasus Pharma Partners with Aptar to Strengthen Commercialisation of Intranasal Epinephrine
The collaboration aims to advance the clinical development and future commercialisation of NS002, Nasus Pharma’s intranasal powder epinephrine product candidate.
Intranasal Epinephrine Product | 13/10/2025 | By Darshana | 110
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy